Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391804 | 1.00 | SPR (0.55) | SPRALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2852200 | 0.87 | SPR (0.51) | SPRALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2857348 | 0.85 | SPR (0.54) | SPRALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3395548 | 0.82 | MAPT (0.49) | ALDH1A1GAAMAPTPOLB | |
| SCHEMBL3391801 | 0.82 | MAPT (0.49) | ALDH1A1GAAMAPTPOLB | |
| SCHEMBL2850723 | 0.78 | TAOK3 (0.47) | ALDH1A1CNR2 | |
| SCHEMBL3390170 | 0.76 | SPR (0.68) | SPRALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3394457 | 0.76 | SPR (0.68) | SPRALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2850487 | 0.76 | HTT (0.48) | ALDH1A1TAS1R3TAS1R1CNR2 | |
| SCHEMBL3423831 | 0.75 | ALDH1A1 (0.55) | SPRALDH1A1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370530-B1 | ACYLATED 1,2,3,4-TETRAHYDRONAPHTHYL AMINES AND THEIR USE AS PHARMACEUTICAL | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-12-29 | — | — | EP | disclosed |
| US-6949556-B2 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-27 | — | — | US | disclosed |
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022935-A1 | Acylated 1,2,3,4-tetrahydronaphthyl amines and their use as pharmaceutical agents | VEGFA, EDNRA, NR1H2 | SPR 4091/4885ALDH1A1 509/4885TAS1R3 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.